ESC 365 - Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

ESC Premium Access

Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

Session: Hot Line: Late-Breaking Clinical Trials 4

Topic: Lipids (Epidemiology and Prevention)

Speaker: Professor M. Landray (Oxford, GB)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Martin Landray

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

7 presentations

0 follower

12 more presentations in this session

Discussant review: Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

Speaker: Professor J. Chapman (Paris, FR)

Panel discussion.

Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

Speaker: Professor H. Itoh (Tokyo, JP)

Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

Speaker: Professor E. Prescott (Copenhagen, DK)

Panel discussion.

Access the full session

Hot Line: Late-Breaking Clinical Trials 4

Speakers: Professor M. Landray, Professor J. Chapman, Professor H. Itoh, Professor E. Prescott

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources